
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, …

Boehringer Ingelheim has moved early to secure an exclusive option on Autifony’s lead candidate for the treatment of schizophrenia, AUT00206, …

GlaxoSmithKline has taken a £1.3 million stake in a new UK biotech spin-out that will develop pharmacological treatments for hearing …